Медицинская литература. Новинки

 

 

 

 

 

 

Стратегия лечения рака поджелудочной железы на современном этапе

Вы можете загрузить полный текст статьи в формате pdf

Ключевые слова:

Литература:
1.Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018; 68 (6): 394-424. http://doi.org/10.3322/caac.21492.
2.Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2019. CA Cancer J. Clin. 2019; 69 (1): 7-34. http://doi.org/10.3322/caac.21551.
3.Society A.A.C. American Cancer Society. Cancer Facts & Figures. 2019.
4.Whipple A.O., Parsons W.B., Mullins C.R. Treatment of carcinoma of the ampulla of vater. Ann. Surg. 1935; 102 (4): 763-779.
5.Griffin J.F., Poruk K.E., Wolfgang C.L. Pancreatic cancer surgery: past, present, and future. Chin. J. Cancer Res. 2015; 27 (4): 332-348. http://doi.org/10.3978/j.issn.1000-9604.2015.06.07.
6.Cameron J.L., Riall T.S., Coleman J., Belcher K.A. One thousand consecutive pancreaticoduodenectomies. Ann. Surg. 2006; 244 (1): 10-15.
7.Meguid R.A., Ahuja N., Chang D.C. What constitutes a “highvolume” hospital for pancreatic resection? J. Am. Coll. Surg. 2008; 206 (4): 622. e1-9. http://doi.org/10.1016/j.jamcollsurg.2007.
8.Neoptolemos J.P., Stocken D.D., Friess H., Bassi C., Dunn J.A., Hickey H., Beger H., Fernandez-Cruz L., Dervenis C., Lacaine F., Falconi M., Pederzoli P., Pap A., Spooner D., Kerr D.J., Buchler M.W. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. 2004; 350 (12): 1200-1210.
9.Oettle H., Neuhaus P., Hochhaus A., Hartmann J.T., Gellert K., Ridwelski K., Niedergethmann M., Zulke C., Fahlke J., Arning M.B., Sinn M., Hinke A., Riess H. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013; 310 (14): 1473-1481. http://doi.org/10.1001/jama.2013.279201.
10.Neoptolemos J.P., Palmer D.H., Ghaneh P., Psarelli E.E., Valle J.W., Halloran C.M., Faluyi O., O''Reilly D.A., Cunningham D., Wadsley J., Darby S., Meyer T., Gillmore R., Anthoney A., Lind P., Glimelius B., Falk S., Izbicki J.R., Middleton G.W., Cummins S., Ross P.J., Wasan H., McDonald A., Crosby T., Ma Y.T., Patel K., Sherriff D., Soomal R., Borg D., Sothi S., Hammel P., Hackert T., Jackson R., Buchler M.W. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, openlabel, randomised, phase 3 trial. Lancet. 2017; 389 (10073): 1011-1024. http://doi.org/10.1016/S0140-6736(16)32409-6.
11.Conroy T. et al. Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas. J. Clin. Oncol. 2018; 36 (18_suppl): LBA4001-LBA4001.
12.Howard T.J., Krug J.E., Yu J., Zyromski N.J., Schmidt C.M., Jacobson L.E., Madura J.A., Wiebke E.A., Lillemoe K.D. A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon''s contribution to long-term survival in pancreatic cancer. J. Gastrointest. Surg. 2006; 10 (10): 1338-1345; discussion 1345-1346.
13.Benassai G., Mastrorilli M., Quarto G., Cappiello A., Giani U., Mosella G. Survival after pancreaticoduodenectomy for ductal adenocarcinoma of the head of the pancreas. Chir. Ital. 2000; 52 (3): 263-270.
14.Millikan K.W. et al. Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. (0003-1348 (Print)).
15.Sohn T., Yeo C.J., Cameron J.L., Koniaris L., Kaushal S., Abrams R.A., Sauter P.K., Coleman J., Hruban R.H., Lillemoe K.D. Resected adenocarcinoma of the pancreas - 616 patients: results, outcomes, and prognostic indicators. J. Gastrointest. Surg. 2000; 4 (6): 567-579.
16.Richter A., Niedergethmann M., Sturm J.W., Lorenz D., Post S., Trede M. Long-term results of partial pancreaticoduoden ectomy for ductal adenocarcinoma of the pancreatic head: 25-Year Experience. World J. Surg. 2003; 27 (3); 324-329.
17.Varadhachary G.R., Tamm E.P., Abbruzzese J.L., Xiong H.Q., Crane C.H., Wang H., Lee J.E., Pisters P.W., Evans D.B., Wolff R.A. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann. Surg. Oncol. 2006; 13 (8): 1035-1046.
18.Nagakawa Y., Nagakawa Y., Sahara Y., Hosokawa Y., Murakami Y., Yamaue H., Satoi S., Unno M., Isaji S., Endo I., Sho M., Fujii T., Takishita C., Hijikata Y., Suzuki S., Kawachi S., Katsumata K., Ohta T., Nagakawa T., Tsuchida A. Clinical impact of neoadjuvant chemotherapy and chemoradio therapy in borderline resectable pancreatic cancer: analysis of 884 patients at facilities specializing in pancreatic surgery. Ann. Surg. Oncol. 2019; 26 (6): 1629-1636. http://doi.org/10.1245/s10434-018-07131-8.
19.Tempero M.A., Malafa M.P., Chiorean E.G., Czito B., Scaife C., Narang A.K., Fountzilas C., Wolpin B.M., Al-Hawary M., Asbun H., Behrman S.W., Benson A.B., Binder E., Cardin D.B., Cha C., Chung V., Dillhoff M., Dotan E., Ferrone C.R., Fisher G., Hardacre J., Hawkins W.G., Ko A.H., LoConte N., Lowy A.M., Moravek C., Nakakura E.K., O''Reilly E.M., Obando J., Reddy S., Thayer S., Wolff R.A., Burns J.L., Zuccarino-Catania G. Pancreatic Adenocarcinoma, Version 1.2019. J. Natl. Compr. Canc. Netw. 2019; 17 (3): 202-210. http://doi.org/10.6004/jnccn.2019.0014.
20.Unno M. et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05). J. Clin. Oncol. 2019; 37 (4_suppl): 189-189.
21.Sohal D. et al. SWOG S1505: Initial findings on eligibility and neoadjuvant chemotherapy experience with mfolfirinox versus gemcitabine/nab-paclitaxel for resectable pancreatic adenocarcinoma. J. Clin. Oncol. 2019; 37(4_suppl): 414-414.
22.Mesleh M.G., Stauffer J.A., Asbun H.J. Minimally invasive surgical techniques for pancreatic cancer: ready for prime time? J. Hepatobiliary. Pancreat. Sci. 2013; 20 (6): 578-582.
23.Palanivelu C., Senthilnathan P., Sabnis S.C., Babu N.S., Srivatsan Gurumurthy S., Anand Vijai N., Nalankilli V.P., Praveen Raj P., Parthasarathy R., Rajapandian S. Randomized clinical trial of laparoscopic versus open pancreatoduodenectomy for periampullary tumours. Br. J. Surg. 2017; 104 (11): 1443-1450. http://doi.org/10.1002/bjs.10662.
24.Poves I., Burdio F., Morato O., Iglesias M., Radosevic A., Ilzarbe L., Visa L., Grande L. Comparison of perioperative outcomes between laparoscopic and open approach for 114 АННАЛЫ ХИРУРГИЧЕСКОЙ ГЕПАТОЛОГИИ, 2019, том 24, №3 ANNALS OF HPB SURGERY, 2019, Vol. 24, N 3 pancreato duodenectomy: The PADULAP Randomized Controlled Trial. Ann. Surg. 2018; 268 (5): 731-739. http://doi.org/10.1097/SLA.0000000000002893.
25.van Hilst J., de Rooij T., Bosscha K., Brinkman D.J., van Dieren S., Dijkgraaf M.G., Gerhards M.F., de Hingh I.H., Karsten T.M., Lips D.J., Luyer M.D., Busch O.R., Festen S., Besselink M.G. Laparoscopic versus open pancreato duodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial. Lancet Gastroenterol. Hepatol. 2019; 4 (3): 199-207. http://doi.org/10.1016/S2468-1253(19)30004-4.
26.Strobel O., Buchler M.W. Laparoscopic pancreatoduodenectomy: safety concerns and no benefits. Lancet Gastroenterol. Hepatol. 2019; 4 (3): 186-187.
27.Adam M.A., Thomas S., Youngwirth L., Pappas T., Roman S.A., Sosa J.A. Defining a hospital volume threshold for minimally invasive pancreaticoduodenectomy in the United States. JAMA Surg. 2017; 152 (4): 336-342. http://doi.org/10.1001/jamasurg.2016.4753.
28.Torphy R.J., Friedman C., Halpern A., Chapman B.C., Ahrendt S.S., McCarter M.M., Edil B.H., Schulick R.D., Gleisner A. Comparing short-term and oncologic outcomes of minimally invasive versus open pancreaticoduodenectomy across low and high volume centers. Ann. Surg. 2018. http://doi.org/10.1097/SLA.0000000000002810.
29.Mirkin K.A., Greenleaf E.K., Hollenbeak C.S., Wong J. Minimally invasive surgical approaches offer earlier time to adjuvant chemotherapy but not improved survival in resected pancreatic cancer. Surg. Endosc. 2018; 32 (5): 2387-2396. http://doi.org/10.1007/s00464-017-5937-7.
30.Bakens M.J., van der Geest L.G., van Putten M., van Laarhoven H.W., Creemers G.J., Besselink M.G., Lemmens V.E., de Hingh I.H. The use of adjuvant chemotherapy for pancreatic cancer varies widely between hospitals: a nationwide populationbased analysis. Cancer Med. 2016; 5 (10): 2825-2831. http://doi.org/10.1002/cam4.921.
31.Wu W., He J., Cameron J.L., Makary M., Soares K., Ahuja N., Rezaee N., Herman J., Zheng L., Laheru D., Choti M.A., Hruban R.H., Pawlik T.M., Wolfgang C.L., Weiss M.J. The impact of postoperative complications on the administration of adjuvant therapy following pancreaticoduodenectomy for adenocarcinoma. Ann. Surg. Oncol. 2014; 21 (9): 2873-2881. http://doi.org/10.1245/s10434-014-3722-6.
32.Chen J.W., Bhandari M., Astill D.S., Wilson T.G., Kow L., Brooke-Smith M., Toouli J., Padbury R.T. Predicting patient survival after pancreaticoduodenectomy for malignancy: histopathological criteria based on perineural infiltration and lymphovascular invasion. HPB (Oxford). 2010; 12 (2): 101-108. http://doi.org/10.1111/j.1477-2574.2009.00140.x.

Modern treatment strategy for pancreatic cancer

Keywords: